The Erchonia FX405 is designed to effectively target muscles and tissues and promote natural healing.
Low level lasers stimulate the body's light sensitive components to produce an effect similar to photosynthesis in plants - "photo-biostimulation".
The cells' mitochondria are stimulated, encouraging the cell to produce more ATP (energy) naturally. This gives the cells more resources to heal.
The FX Series uses low-level laser technology and patented laser diode arms to precisely target neck and back pain centers. It reduces inflammation while promoting bio-stimulation at a cellular level in the musculoskeletal point of the pain’s origin.
The FX Series has been FDA Cleared for treating overall body chronic pain and heel pain associated with Plantar Fasciitis.
Erchonia's Got Your Back
No pain | No Drugs | No side-effects
There are a number of applications for Erchonia Corporation’s groundbreaking laser devices. Based on Erchonia’s Level one clinical study results in 2002, the FDA found it necessary to create a new regulatory category of medical devices: NHN Biostimulation lasers.
About 80 percent of adults experience low back pain at some point in their lifetimes. Of those, about 60% are treated with opioids, despite the opioid epidemic and minimum effectiveness (30%). Erchonia’s FX 635 laser showed a 72% success rate in their clinical trial, which received FDA market clearance in May 2018. The FX 635 treatment of chronic low back pain is groundbreaking in the pain management community and gives patients a safer, more effective treatment option that will get them back on their feet in no time.
Erchonia low level lasers are proven to be effective in reducing and eliminating chronic pain in the neck & shoulders. Many patients find that this solution is a much more effective and immediate alternative to traditional pain medications. The Erchonia lasers have been proven through rigorous clinical trials in which subjects had to refrain from any therapies, besides the laser. However in practice doctors are combining forms of chiropractic and therapy, to help patients lead a normal, active, and healthy life without debilitating pain.
Plantar fasciitis is the most common cause of heel pain in adults, affecting 1 million persons each year in the United States. Treatment ranges from rest to surgical intervention. Erchonia’s LLLT has received FDA clearance as an adjunct treatment for Plantar Fasciitis due to the treatment’s safe and efficacious nature. In a 3 week study, on average individuals experienced a 50% reduction in pain, with pain reduction either improving or sustaining up to 12 months post treatment.